Morgan Stanley Imago Bio Sciences, Inc. Transaction History

Morgan Stanley

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$15.03 - $35.96 $38,416 - $91,913	-2,556 Reduced 25.63%	7,415 $266,000
Q3 2022 Nov 14, 2022	SELL	$14.15 - $19.5 $8,645 - $11,914	-611 Reduced 5.77%	9,971 $150,000
Q2 2022 Oct 27, 2022	SELL	$11.81 - $20.92 $65,332 - $115,729	-5,532 Reduced 34.33%	10,582 $142,000
Q2 2022 Aug 15, 2022	SELL	$11.81 - $20.92 $65,332 - $115,729	-5,532 Reduced 34.33%	10,582 $142,000
Q1 2022 Oct 27, 2022	BUY	$16.97 - $25.0 $93,878 - $138,300	5,532 Added 52.28%	16,114 $311,000
Q1 2022 May 13, 2022	BUY	$16.97 - $25.0 $125,561 - $184,975	7,399 Added 84.9%	16,114 $311,000
Q4 2021 Feb 14, 2022	BUY	$16.22 - $29.69 $100,855 - $184,612	6,218 Added 249.02%	8,715 $207,000
Q3 2021 Nov 15, 2021	BUY	$16.0 - $28.84 $39,952 - $72,013	2,497 New	2,497 $50,000

19.3K

Ticker IMGO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,741,600
Description
Imago BioSciences, Inc., a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow. Its lead product candidate is bomedemstat, which is in Phase II clinical trials for the treatment o...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.